14150-64-2

Basic information

• Product Name: hydrazinoacetic acid
• Synonyms: hydrazinoacetic acid;Einecs 237-995-8
• CAS NO: 14150-64-2
• Molecular Formula: C₂H₆N₂O₂
• Molecular Weight: 90.08124
• EINECS: 237-995-8
• Mol File: 14150-64-2.mol

Chemical Properties

• Boiling Point: 366.8°C at 760 mmHg
• Flash Point: 175.6°C
• Appearance: /
• Density: 1.311g/cm³
• Vapor Pressure: 2.21E-06mmHg at 25°C
• Refractive Index: 1.494
• CAS DataBase Reference: hydrazinoacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: hydrazinoacetic acid(14150-64-2)
• EPA Substance Registry System: hydrazinoacetic acid(14150-64-2)

Safety Data

• Hazardous Substances Data: 14150-64-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Hydrazinoacetic acid is used as an IL-17 and IFN-γ inhibitor for treating autoimmune diseases and chronic inflammation. By inhibiting these inflammatory cytokines, hydrazinoacetic acid can help modulate the immune response and alleviate symptoms associated with various autoimmune conditions and chronic inflammatory disorders. This makes it a promising candidate for the development of novel therapeutics in the pharmaceutical industry.

InChI:InChI=1/C2H6N2O2/c3-4-1-2(5)6/h4H,1,3H2,(H,5,6)

Upstream product

• 48046-92-0 semicarbazido-acetic acid 
• 79-11-8 chloroacetic acid 
• 623-73-4 diazoacetic acid ethyl ester 
• 503-68-4 diazoacetic acid 
• 115262-99-2 2-[2-(tert-butoxycarbonyl)hydrazinyl]acetic acid 
• 6945-92-2 2-hydrazinyl acetic acid ethyl ester hydrochloride 
• 777011-18-4 N-hydroxy-N-nitroso-glycine 
• 7664-93-9 sulfuric acid 
• 79-08-3 bromoacetic acid 
• 139397-88-9 ethoxycarbonylhydrazono-acetic acid 

Downstream Products

• 63981-22-6 3-(5-nitrofurfurylideneamino)hydantoic acid 
• 18523-48-3 2-azidoacetic acid 
• 6945-92-2 2-hydrazinyl acetic acid ethyl ester hydrochloride 
• 138-07-8 2-semicarbazide acetic acid 

Relevant articles and documents

N-Amino-1,8-Naphthalimide is a Regenerated Protecting Group for Selective Synthesis of Mono-N-Substituted Hydrazines and Hydrazides

A new route to synthesis of various mono-N-substituted hydrazines and hydrazides by involving in a new C?N bond formation by using N-amino-1,8-naphthalimide as a regenerated precursor was invented. Aniline and phenylhydrazines are reproduced upon reacting these individually with 1,8-naphthalic anhydride followed by hydrazinolysis. The practicality and simplicity of this C?N dihalo alkanes; developed a synthon for bond formation protocol was exemplified to various hydrazines and hydrazides. N-amino-1,8-naphthalimide is suitable synthon for transformation for selective formation of mono-substituted hydrazine and hydrazide derivatives. Those are selective mono-amidation of hydrazine with acid halides; mono-N-substituted hydrazones from aldehydes; synthesis of N-aminoazacycloalkanes from acetohydrazide scaffold and inserted to hydroxy derivatives; distinct synthesis of N,N-dibenzylhydrazines and N-benzylhydrazines from benzyl halides; synthesis of N-amino-amino acids from α-halo esters. Ecofriendly reagent N-amino-1,8-naphthalimide was regenerated with good yields by the hydrazinolysis in all procedures.

Synthesis method of ethyl hydrazinoacetate hydrochloride

The invention discloses a synthesis method of ethyl hydrazinoacetate hydrochloride and belongs to the technical field of organic synthesis. The technical scheme is characterized in that chloroacetic acid is used as an initial material to react with hydrazine hydrate to produce intermediate hydrazine acetic acid, hydrazine acetic acid and ethanol form ester to obtain ethyl hydrazinoacetate, a hydrogen chloride solution is added to react to obtain a crude product of ethyl hydrazinoacetate hydrochloride, and high-purity ethyl hydrazinoacetate hydrochloride is obtained through refinement. The method has the advantages of being mild in reaction condition, high in yield, high in purity, low in cost, economical, environmentally friendly, applicable to industrialization and the like and is a synthesis method with industrial production values.

STRAIGHT-CHAIN AND BRANCHED-CHAIN LIPID COMPOUNDS AS SELECTIVE INHIBITORS OF CYCLOOXYGENASE-2, ANTI-INFLAMMATORY AGENTS, AND ANTI-CANCER AGENTS

Unique branched-chain lipid compounds are disclosed as selective COX-2 inhibitors, which are derivatives of a branched-chain fatty amine or a branched-chain fatty amide, or a pharmaceutically acceptable salt thereof. The compounds can be used for osteoarthritis and rheumatoid arthritis as anti-inflammatory agents, in addition to treating and preventing cancer. Straight-chain analogs of the branched-chain lipid compounds provide similar uses.

Solution phase synthesis of imidazo[1,2-b]pyrazol-2-one, an interesting 5,5-fused heterocyclic ring system

The solution phase synthesis of a series of imidazo[1,2-b]pyrazol-2-ones, a fused 5,5-ring system, based on diverse set of hydrazino acids and malononitriles is described. The method involves formation of 5-aminopyrazoles followed by intra-molecular cyclodehydration.

Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid

3-Guanidinopropionic acid (1) has been demonstrated both to improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). However, 1 has also been shown to be a substrate for both the creatine transporter and creatine kinase, leading to marked accumulation in muscle tissue as the corresponding N-phosphate. The corresponding aminoguanidine analogue 2 was recently discovered to retain the antidiabetic activity of 1 while being markedly less susceptible to creatine-like metabolism, suggesting that it should have less potential to accumulate in muscle. Further structural modification of 2 was undertaken to investigate whether the antidiabetic potency could be augmented while maintaining resistance to creatine-like metabolism. Modifications such as α-alkylation, homologation, and bioisosteric replacement of the aminoguanidine all were detrimental to antidiabetic activity. However, the simple regioisomeric aminoguanidinoacetic acid 9 and diaminoguanidinoacetic acid analogue 7 were found to be equipotent to 2, leading eventually to the discovery of the significantly more potent diaminoguanidinoacetic acid regioisomers 52 and 53. Further attempts to modify the more active template represented by 52 led only to reductions in antidiabetic activity. Each of the new active analogues displayed the same resistance to creatine-like metabolism as 2. Further testing of 7, 9, and 53 in obese diabetic ob / ob mice confirmed that weight loss is induced selectively from adipose tissue, similar to the lead 1. Administration of 53 to insulin-resistant rhesus monkeys led to reductions in both fasting and post-prandial plasma glucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound improved the action of endogenous insulin. Compounds 7 and 53 were selected for further preclinical development.

Gut-selective opiates

Gut-selective agonist or antagonist opiates of the formula: STR1 wherein R is (C1 -C5)alkyl, C3 -C6 (cycloalkyl)alkyl, aryl, aralkyl or trans-(C2 -C5)alkenyl; Z is H or OH, R' is (C=O)-A(B)(C) wherein A is selected from the group consisting of (C1 -C5)alkyl, (C2 -C5)alkenyl and (C2 -C6)alkoxy (alkyl); B is selected from the group consisting of H, amino and a (C1 -C5)alkyl group optionally substituted with CO2 H, OH or phenyl and C is CO2 H, SO3 H, amino or guanidino; and R" is selected from the group consisting of NH-A(B)(C) or is guanidino; and the pharmaceutically-acceptable salts thereof.